Rapid, large-scale generation of highly pure cytomegalovirus-specific cytotoxic T cells for adoptive immunotherapy.

Aaron E Foster, David J Gottlieb, Marina Marangolo, Anna Bartlett, Yi-Chiao Li, Geoffrey W Barton, Jose A Romagnoli, Kenneth F Bradstock
{"title":"Rapid, large-scale generation of highly pure cytomegalovirus-specific cytotoxic T cells for adoptive immunotherapy.","authors":"Aaron E Foster,&nbsp;David J Gottlieb,&nbsp;Marina Marangolo,&nbsp;Anna Bartlett,&nbsp;Yi-Chiao Li,&nbsp;Geoffrey W Barton,&nbsp;Jose A Romagnoli,&nbsp;Kenneth F Bradstock","doi":"10.1089/152581603321210172","DOIUrl":null,"url":null,"abstract":"<p><p>Adoptive transfer of donor-derived cytomegalovirus (CMV)-specific cytotoxic T cell (CTL) clones can restore immunity in allogeneic stem cell transplant recipients, providing protection against CMV disease. Current methods for selecting and expanding CMV-specific T cell clones are technically difficult, making adoptive T cell therapy impractical for routine clinical use. In this study, we describe a method for ex vivo generation and expansion of high-purity CMV-specific CTL using peptide-pulsed dendritic cells as antigen-presenting cells. Generation of CMV-specific CTL in numbers sufficient for clinical use in the time span of 4 weeks was accomplished in 6 of 8 CMV-seropositive donors. Examination of pp65 specificity by HLA/peptide tetramer staining demonstrated that a purity of greater than 95% peptide-specific cells could be obtained after two weekly stimulations and retained after further expansion for 3-4 weeks. Median expansion of total cell number was greater than 500-fold and expansion of peptide-specific CTL by tetramer staining was greater than 1.7 x 10(5)-fold. Four weeks after initiating CTL culture, we were able to generate greater than 10(9) total cells that specifically lysed target cells loaded with CMV peptide and cells infected with CMV. This simple and rapid method for generating high-purity CMV-specific CTL for adoptive immunotherapy is currently being examined for routine clinical use for allogeneic stem cell transplantation.</p>","PeriodicalId":80030,"journal":{"name":"Journal of hematotherapy & stem cell research","volume":"12 1","pages":"93-105"},"PeriodicalIF":0.0000,"publicationDate":"2003-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/152581603321210172","citationCount":"18","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of hematotherapy & stem cell research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/152581603321210172","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 18

Abstract

Adoptive transfer of donor-derived cytomegalovirus (CMV)-specific cytotoxic T cell (CTL) clones can restore immunity in allogeneic stem cell transplant recipients, providing protection against CMV disease. Current methods for selecting and expanding CMV-specific T cell clones are technically difficult, making adoptive T cell therapy impractical for routine clinical use. In this study, we describe a method for ex vivo generation and expansion of high-purity CMV-specific CTL using peptide-pulsed dendritic cells as antigen-presenting cells. Generation of CMV-specific CTL in numbers sufficient for clinical use in the time span of 4 weeks was accomplished in 6 of 8 CMV-seropositive donors. Examination of pp65 specificity by HLA/peptide tetramer staining demonstrated that a purity of greater than 95% peptide-specific cells could be obtained after two weekly stimulations and retained after further expansion for 3-4 weeks. Median expansion of total cell number was greater than 500-fold and expansion of peptide-specific CTL by tetramer staining was greater than 1.7 x 10(5)-fold. Four weeks after initiating CTL culture, we were able to generate greater than 10(9) total cells that specifically lysed target cells loaded with CMV peptide and cells infected with CMV. This simple and rapid method for generating high-purity CMV-specific CTL for adoptive immunotherapy is currently being examined for routine clinical use for allogeneic stem cell transplantation.

用于过继免疫治疗的高纯度巨细胞病毒特异性细胞毒性T细胞的快速、大规模生成。
供体来源巨细胞病毒(CMV)特异性细胞毒性T细胞(CTL)克隆的过继转移可以恢复同种异体干细胞移植受者的免疫力,提供对巨细胞病毒疾病的保护。目前选择和扩增cmv特异性T细胞克隆的方法在技术上是困难的,这使得过继T细胞治疗在常规临床应用中不切实际。在这项研究中,我们描述了一种利用肽脉冲树突状细胞作为抗原呈递细胞体外生成和扩增高纯度cmv特异性CTL的方法。在8例cmv血清阳性供者中,有6例在4周内产生了足以用于临床的cmv特异性CTL。HLA/肽四聚体染色检测pp65特异性表明,经过两周的刺激后,可以获得纯度大于95%的肽特异性细胞,并在进一步扩增后保留3-4周。总细胞数中位数扩增大于500倍,四聚体染色的肽特异性CTL扩增大于1.7 × 10(5)倍。启动CTL培养4周后,我们能够产生超过10(9)个细胞,这些细胞特异性地裂解了装载巨细胞病毒肽的靶细胞和感染巨细胞病毒的细胞。这种简单快速的方法产生高纯度cmv特异性CTL用于过继免疫治疗,目前正在研究用于同种异体干细胞移植的常规临床应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信